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Objectives: Abnormal uterine bleeding (AUB) interferes with physical, emotional, 
and social well-being, impacting the quality of life of more than 10 million women in 
the US. Hysterectomy, the most common surgical treatment of AUB, has significant 
morbidity, low mortality, long recovery, and high associated health care costs. Global 
endometrial ablation (GEA) provides a surgical alternative with reduced morbid-
ity, cost, and recovery time. The NovaSure system utilizes unique radiofrequency 
impedance-based GEA technology. This study evaluated cost-effectiveness of AUB 
treatment with NovaSure ablation versus other GEA modalities and versus hys-
terectomy from US commercial and Medicaid payer perspectives. MethOds: A 
health state transition (semi-Markov) model was developed using epidemiologic, 
clinical, and economic data from commercial and Medicaid claims database analy-
ses, supplemented by published literature. Three hypothetical cohorts of women 
receiving AUB interventions were simulated over 1-, 3-, and 5-year horizons to 
evaluate clinical and economic outcomes for NovaSure, other GEA modalities, and 
hysterectomy. Results: Model analyses show lower costs for NovaSure-treated 
patients than for those treated with other GEA modalities or hysterectomy over 
all timeframes under commercial payer and Medicaid perspectives. By Year 3, cost 
savings versus other GEA were $930 (commercial) and $3,000 (Medicaid); cost savings 
versus hysterectomy were $6,500 (commercial) and $8,900 (Medicaid). Coinciding 
with a 43%-71% reduction in need for re-ablation, there were 69%-88% fewer inter-
vention/reintervention complications for NovaSure-treated patients versus other 
GEA modalities, and 82%-91% fewer versus hysterectomy. Furthermore, NovaSure-
treated patients had fewer days of work absence and short-term disability. Cost-
effectiveness metrics showed NovaSure treatment as economically dominant over 
other GEA modalities in all circumstances. With few exceptions, similar results were 
shown for NovaSure treatment versus hysterectomy. cOnclusiOns: Model results 
demonstrate strong financial favor for NovaSure ablation versus other GEA modali-
ties and hysterectomy from commercial and Medicaid payer perspectives. Results 
will interest clinicians, health care payers, and self-insured employers striving for 
cost-effective AUB treatments.
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LIfetIme HeaLtH and economIc consequences of obesIty-ReLated 
dIseases: usIng data fRom tHe natIonaL HeaLtH InteRvIew suRvey, 
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Objectives: This study analyzed lifetime health and economic consequences of 
multiple obesity-related diseases (ORDs), including diabetes, hypertension, coro-
nary heart disease (CHD), and stroke. MethOds: Nationally representative data 
of the U.S. civilian, non-institutionalized population was used. Our sample was 
from the National Health Interview Survey (NHIS), 1997-2000, and linked to the 
NHIS Linked Mortality Public-Use Files to estimate mortality risks. The sample was 
further linked to the Medical Expenditure Panel Survey (MEPS) to estimate annual 
health care expenditures. Disease risks were estimated with National Health and 
Nutrition Examination Survey (NHANES) data. Analyses were stratified by gender 
and adjusted for age, race, and BMI groups. Complex sampling designs in NHIS, 
MEPS, and NHANES were adjusted for. A Markov model populated by estimates 
of disease and mortality risks and health care expenditures was built to compute 
life years and lifetime health care expenditures for gender-race-age-BMI-specific 
subpopulations. Results: Our sample comprised of 17,917 women and 13,928 men. 
For individuals age 40, life years lost associated with ORDs for women ranged from 
2.7 (obese, not white or black, with CHD) to 14.6 (normal-weight, white, with all 
four ORDs) and for men from 2.3 (obese, not white or black, with diabetes) to 12.4 
(normal-weight, not white or black, with all four ORDs). Lifetime health care expend-
iture increment associated with ORDs for women ranged from $27,749 (normal-
weight, white, with hypertension) to $277,949 (overweight, not white or black, with 
all four ORDs) and for men from $41,804 (normal-weight, black, with hypertension) 
to $249,829 (overweight, not white or black, with all four ORDs). cOnclusiOns: This 
study suggests that the lifetime health and economic consequences associated with 
ORDs are higher for women than men. And disease burden increases with increas-
ing number of ORDs. Diabetes is the most costly ORD. Among sets of two ORDs, the 
combination of diabetes and hypertension is the most costly.
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Objectives: Compare health care costs and resource utilization between patients 
with Peyronie’s disease (PD) and matched controls without PD. MethOds: Male 
adults aged ≥ 65 in Medicare Advantage plans or aged 18-64 in commercial plans 
with ≥ 1 PD diagnosis (ICD-9-CM: 607.85) between 1/1/2007-12/31/2012 were selected 
from a national claims database comprised of 14M enrollees. The index date was 
defined as the observed first date with a PD diagnosis. Continuous eligibility for ≥ 6 
months before (baseline period) and 1 year after (study period) the index date was 
required. PD patients (cases) were matched on age, gender, race, geographic region, 
plan type, index year, baseline health care costs and comorbidities to patients with-
out PD, Dupuytren’s contracture, or Ledderhose disease diagnoses in their claims 
histories (controls) by propensity score matching. Descriptive analyses compared 
baseline characteristics and post-index resource utilization between cohorts. As 
indicated by Box-Cox test and Park test, generalized linear models with gamma 
distribution and log link were used to compare risk-adjusted health care costs 
inflated to $2013 US dollars. Results: 1,528 Medicare PD patients (mean age 70 
years) and 768 commercial patients (mean age 51 years) met the inclusion criteria. 
PD patients had significantly higher comorbidities compared with their controls 
(e.g., erectile dysfunction (ED), other male genital organs diseases, urinary diseases, 
diabetes and hyperlipidemia) (all p< .05). During the study period, PD patients had 
compare the different methods adopted for the detection of the ADRs. MethOds: 
A prospective observational study was carried out at the three general wards of 
medicine department of an Indian public teaching hospital. The three different 
scales for causality assessment used were Naranjo‘s ADR probability scale, WHO-
UMC causality category and, Karch and Lasagna scale. Results: Only 60 ADRs were 
identified in 520 patients studied. All the identified ADRs were assessed for causality 
using different causality assessment scales. According to Naranjo‘s ADR probability 
scale, 52 of the reactions were ‘probable’, 8 of the reactions were ‘possible. 28 ADRs 
were ‘probable’ and 32 were ‘possible’, according to WHO-UMC causality category. 
According to Karch and Lasagna scale, 45 ADRs were ‘probable’ and 15 were ‘pos-
sible’. A comparison between three scales showed that there is a closer match in 
the ‘probable’ ADRs between Naranjo and Karch & Lasgna scales (87% & 75%), 45% 
ADRs were probable (WHO-UMC method). Out of these three methods WHO-UMC 
method was found to be simple to use. cOnclusiOns: Causality assessment helps 
to assess the link between the drug and the ADRs. There is a disagreement between 
the outcomes of the study when three methods were used for causality assessment 
of reported ADRs.
IndIvIduaL’s HeaLtH – cost studies
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budget ImPact of utILIzIng vaRIous tyPes of advanced bIPoLaR 
eneRgy (abe) devIces veRsus conventIonaL bIPoLaR eneRgy (cbe) In 
totaL LaPaRoscoPIc HysteRectomy In canadIan HosPItaLs
Ondrejicka D.A., Goldstein L.J.
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Objectives: Electrosurgical instruments have proven to be effective at achieving 
hemostasis in laparoscopic hysterectomy and in Canada, their usage is increas-
ing. ABE devices have several advantages over conventional bipolar energy (CBE) 
including decreased thermal damage to tissue, improved ease-of-use and greater 
physician control. While all ABE devices have advantages over CBE technology, each 
of the 3 available ABE systems impact procedure time and length of stay differ-
ently. One disadvantage of all 3 ABE systems is the premium pricing as compared 
to CBE. This study was conducted to determine the budget impact of switching 
from CBE to 3 different ABE systems for benign laparoscopic hysterectomies in 
Canadian hospitals. MethOds: The budget impact model considers the inpatient 
and procedural costs incurred by a Canadian hospital performing 100 procedures 
annually. CBE is utilized as a baseline for efficacy and each of the 3 ABE systems 
are compared to CBE individually. Data on the use of health care resources was 
obtained from published prospective randomized/non-randomized controlled trials. 
Additional costing data was obtained from the Ontario Case Costing Initiative and 
a large Canadian hospital. The device costs were collected from market research. 
A multivariate sensitivity analysis using a Monte Carlo simulation was completed 
to ensure scientific rigour. Results: When comparing the 3 forms of ABE to CBE, 
EnSeal was the only technology that significantly reduced both OR time and length 
of stay. This reduction in health care resources offsets Enseal’s premium price result-
ing in an equivalent budget impact to CBE. However, the other 2 ABE systems do 
not show a reduction in OR time or length of stay and as a result, cost a Canadian 
hospital on average $30,239.93 and $93,091.44 more than CB or EnSeal per annum 
for laparoscopic hysterectomies. cOnclusiOns: EnSeal is as cost-effective as CBE 
for benign laparoscopic hysterectomies in a Canadian hospital.
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cost anaLysIs of tHe RobotIc suRgeRy In ItaLy
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Objectives: The purpose of the study is to determine the cost of robotic surgery in 
comparison with traditional surgery, both in the NHS and societal perspective, in 
the Italian setting. MethOds: The prospective multicentre study performed a cost 
analysis on about 700 patients enrolled for the period February 2011 - December 2013 
in 8 Italian Hospitals. The interventions were general, thoracic and gynaecological 
surgery performed with open, laparoscopic or robotic technique. The model was 
developed considering both direct and indirect costs in the various phases of the 
intervention: patients enrollment and hospitalization, first follow up one month 
after discharge, next follow up. The model used tariffs for direct health care costs 
as laboratory, instrumental tests and specialist visits. For all other health care direct 
costs, non health care direct costs and indirect costs the model used real costs and 
resources data. Results: In NHS perspective all specialties of robotic and open 
interventions cost 9,471€ vs 7,232€ , p< 0.01. Indirect costs are lower in robotics ver-
sus open: 928€ vs 872€ , p< 0.05; this could be explained by lower length of stay of 
robotic vs open (7.78 days versus 6.41, p< 0.01). In the societal perspective, costs for 
all specialties (robotics: 10,909€ ; open: 8,681€ ; laparoscopic: 8,303€ ), show differ-
ences between robotic and traditional surgery, as open and laparoscopic interven-
tions present the same level of total costs. cOnclusiOns: Robotic surgery is more 
expensive than traditional techniques, the operating times decrease with increasing 
experience of the surgeon in the use of the robot. It is important to highlight the 
benefits of the use of the robot in terms of ease of execution of complex interven-
tions by both surgeon and experienced assistant. This should also have a positive 
impact on the quality of life of patients who should receive a level of postoperative 
pain in the lower robotic interventions.
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cost-effectIveness of endometRIaL abLatIon wItH tHe novasuRe® 
system veRsus otHeR gLobaL abLatIon modaLItIes and HysteRectomy 
foR tReatment of abnoRmaL uteRIne bLeedIng (aub): unIted states 
commeRcIaL and medIcaId PayeR PeRsPectIves
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During the first two years’ follow-up, hospital admissions were significantly lower 
in controls (p< 0.0001 vs PAP for both years); number of admissions was 5,323 in 
the control group and 6,931 in the PAP group. Conversely, in year 3 of follow-up, the 
number of inpatient treatments was significantly lower in the PAP vs control group 
(1,525 vs 2,000; p< 0.0001). Total cost of illness was higher in the PAP group compared 
with controls (year 1: € 6,704 vs € 5,015 [p< 0.0001]; year 2: € 5,272 vs € 4,901 [p< 0.001]; 
year 3: € 5,091 vs € 4,830 [p< 0.001]). Recipients of PAP therapy had a significantly 
lower 3-year mortality rate compared with controls (4.5% vs 7.2%; p< 0.0001; rela-
tive risk reduction 37.5%). cOnclusiOns: SA patients with PAP therapy showed a 
significantly reduced mortality and morbidity. Also, the data showed that treatment 
may begin to have beneficial effects on the hospitalisation rate after 2 years of treat-
ment. Costs of PAP remained higher than control over the first 3 years of therapy, 
although the difference between treatment groups reduced over time. A follow-up 
period of ≥ 5 years may be required to show beneficial economic outcomes in SA 
patients receiving PAP therapy.
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PsycHIatRIc HeaLtH caRe utILIsatIon and ReLated costs In newLy 
dIagnosed PatIents wItH autIsm sPectRum dIsoRdeR (asd) In quebec 
(canada)
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Objectives: To characterize psychiatric health care utilization and its related costs in 
a cohort of newly diagnosed ASD individuals. MethOds: A cohort was built using the 
provincial public health care insurance program (RAMQ) databases. Newly diagnosed 
subjects with ASD were selected (≥ 2 diagnoses (separate dates) with ICD-9 codes: 
299.X, excluding 299.2) between January 1998 and December 2010. Cohort entry was 
the date of first diagnosis confirmed by the absence of ASD diagnosis in previous 5 
years. Participants aged ≥ 26 years or those not covered by the RAMQ drug plan in the 
year preceding cohort entry were excluded. Demographic and clinical patient charac-
teristics were done at cohort entry. Health care utilisation associated with a psychi-
atric diagnosis (physician and emergency room visits, hospitalisations), psychoactive 
drug use (anticonvulsants, antipsychotics, antidepressants, anxiolytics, ADHD drugs) 
and total cumulative costs were assessed across 5 years of follow-up. Results: A 
number of 1227 patients among the total cohort had 5 years of follow-up (male: 80.3%; 
median age: 7 years). In the 1-year following diagnosis, the mean number of visits to 
general practitioners was 1.6 whereas psychiatry related visits to specialists were 7.2 
which decreased over time. Psychoactive drug utilisation was initially present in 49.3% 
of participants, and increased to 53.2% at 5 years. The psychiatric hospitalization rate 
was 10.4% in the 1-year of follow-up with the highest rates seen in adolescents (20%) 
and young adults (24%). Cumulative costs of psychiatric health services and psycho-
active drugs at 1-year of follow-up were $547,568CAD and $600,433CAD, respectively. 
Those costs were at $216,827CAD and $934,381CAD at 5-years. cOnclusiOns: While 
cost related to psychiatric health care services decreased by more than half in the 5 
years of follow-up, drug costs rose by 56%. Access to long term care and monitoring 
among the ASD population is discussed.
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Objectives: Endometriosis takes the third place in the structure of the gyneco-
logical pathology after inflammatory diseases of the female genital organs and 
uterine fibroids. Endometriosis is most commonly diagnosed in women between 
30 and 40 years of age - reproductive and functional age. The aim of the study was 
to calculate the average cost of hormonal therapy of endometriosis in Ukraine for 
a minimum period of 6 months, considering that the main aim of this therapy 
is the elimination of two major problems such as endometriosis-associated pain 
(dysmenorrhea, dyspareunia, chronic pelvic pain, ovulation-related pain, dysche-
zia) and infertility. MethOds: We analyzed the cost of treatment hormones per 
patient for course. We used the real data from medical records of patients who were 
treated in a regional perinatal center in Lviv. We have analyzed almost 150 stories 
diseases for 2012-2013. We used the prices from Ukrainian database of Morion com-
pany (Kiev) on 01.01.2014 (1 USD = 8,24 UAH). Results: In Ukraine for treatment 
of endometriosis often use these three alternative treatment hormonal schemes. 
We calculated the costs for course per patient in 6 months duration. The treatment 
costs are Dydrogesterone (tab. 10 mg №20) - 345 USD (2843 UAH); Dienogest (tab. 2 mg 
№28) - 550 USD (4530 UAH); Triptorelin (powder for susp. for injection 3,75 mg) - 1347 
USD (11097 UAH). cOnclusiOns: The alternative hormonal treatment schemes of 
endometriosis are differences 4 times per 1 patient for 6 months duration. Almost 
patient fully pay costs out of pocket, through this treatment costs are quite high for 
Ukrainian women. These results support the need to provide some state funding 
for the treatment of endometriosis and introduction the reimbursement system for 
hormonal medicine in Ukraine.
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tHe cost-effectIveness of PosItRon emIssIon tomogRaPHy (Pet): a 
systematIc RevIew acRoss muLtIPLe IndIcatIons
Cangelosi M.J, Saunders T., Neumann P.J., Chambers J.D.
Tufts Medical Center, Boston, MA, USA
Objectives: To review the cost-effectiveness literature evaluating positron emis-
sion tomography (PET) imaging. MethOds: We systematically searched the PubMed 
database and the Tufts Medical Center Cost-Effectiveness Analysis Registry to 
identify studies evaluating the economics of PET imaging. We categorized each 
study with respect to indication, i.e., cardiology, neurology, oncology, and other. 
We extracted data pertaining to: the date of publication; the region in which the 
significantly (p< 0.01) higher rates of outpatient visits, ambulatory surgical center 
visits, physical therapy visits, anti-depressant use and ED prescription use com-
pared to controls. Compared with their controls, Medicare PD patients had on 
average significantly higher risk-adjusted all-cause outpatient costs ($5,322 vs. 
$3,162) and annual all-inclusive health care costs ($10,675 vs. $7,926); risk-adjusted 
annual total all-cause costs for the commercial cohort were $10,463 vs. $5,918 (all 
p< 0.0001). cOnclusiOns: PD patients had higher comorbidity rates, utilization, 
and annual total costs compared with matched controls.
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IncRementaL HosPItaL costs assocIated wItH comoRbIdItIes of 
PRematuRIty
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Objectives: Hospital costs for newborns are indirectly associated with gestational 
age (GA) at birth. The higher costs of prematurity are primarily a function of the 
presence of clusters of comorbidities. The objective of this study was to explore 
the incremental costs associated with having neonatal comorbidities of prematu-
rity, and whether stable cost estimates can be derived for use in economic evalua-
tions. MethOds: Our analyses included 4292 hospital records from infants (23-37 
wks GA) born to mothers with uncomplicated singleton pregnancies in spontane-
ous preterm labor at the Medical University of South Carolina from 2001-2010 . 
Thirteen comorbidities associated with prematurity were identified: respiratory 
distress syndrome (RDS), bronchopulmonary dysplasia (BPD), sepsis, meningitis, 
necrotizing enterocolitis (NEC), intraventricular hemorrhage I & II and III & IV (IVH 
I/II & IVH III/IV), periventricular leukomalacia (PVL), anemia, apnea, retinopathy 
of prematurity requiring surgery (ROP), convulsions, and brain injury (PVL/CPV). 
To estimate incremental cost of each, adjusted for other comorbidities and GA, 
we transformed the data and implemented a partial least squares model, with 10 
fold-cross validation of the full model. Results: Transformation of the data and 
implementation of the partial least squares model eliminated collinearity issues 
in the data leading to stable incremental cost estimates, Q2= 0.69. The model was 
found to be stable under bootstrapping. Cost outliers were retained in the model as 
the incremental costs estimates were stable and the model had good predictability 
when they were retained. Incremental costs ranged from $23,121 (ROP) to $4,529 
(convulsions). cOnclusiOns: In addition to GA at birth, these 13 comorbidities of 
prematurity impact total hospital costs of premature infants. This study provides 
reliable estimates of the incremental cost associated with comorbidities of prema-
turity, controlling for GA at birth, to be used in future economic analyses of the cost 
associated with premature birth due to spontaneous preterm labor.
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Objectives: To estimate the economic burden of unintended pregnancy in the 
perspective of public payer and the impact of UP on related public health meas-
ures in Brazil. MethOds: A decision-analysis cost model was constructed based 
on pregnancy rates, probabilities and costs of pregnancy and neonatal outcomes 
(miscarriage, induced abortion, and live birth) in Brazil. The model took account of 
both maternal and child outcomes, and accounted for health care costs related with 
preterm birth, neonatal admission, cerebral palsy, neonatal and maternal mortality. 
All costs are reported as Real$ (Brazilian currency). Results: In Brazil there were 1.8 
million unintended pregnancies in 2010. Those unintended pregnancies resulted in 
159,151 miscarriages, 48,769 induced abortions, and 1.58 million live births. It was 
estimated there were 312 maternal deaths. The number of infant deaths within the 
12-months following birth was estimated at 32,864. The total health care costs to 
public payer attributed to unintended pregnancies are estimated to be R$4.1 billion 
in one year of which R$4.07 billion (99.2%) attributed to births and resulting com-
plications and R$32 million (0.8%) was attributed to miscarriage. The average cost 
per UP was R$2,293. cOnclusiOns: Unintended pregnancies impose substantial 
burden on the Brazilian society in term of health care costs, infant and maternal 
morbidity and mortality. Reduction in UPs will not only generate substantial cost-
savings, but also improve public health profile of the country. Public policymakers 
should allocate budget on cost-effective pregnancy prevention interventions to 
address this issue.
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Objectives: Sleep apnea (SA) is relatively common, occurring in about 2–4% of the 
general population. This study investigated the effects of PAP therapy on morbidity 
(including comorbid disease), all-cause mortality, and costs in patients with SA. 
A statutory health insurance (SHI) perspective was taken. MethOds: A total of 
approx. 4 million individuals covered by the SHI database were analysed (ca. 5% of 
the German SHI population). PAP therapy was initiated in 4068 patients with SA. 
Propensity score was used to define a control group of 4068 SA patients matched 
for age, sex, risk factors/etiology, region and medication who received usual care 
(no PAP). Patients were followed after therapy initiation over three years. Results: 
